Clinical Trials
Currently Active (recruiting)
SNB-101 – Solid Tumor(NCT04640480)
The Phase 1 Study (SNB101P01) is a accelerated dose finding study with 21 solid tumor patients who had progression after prior standard of care treatment, and we assessed safety, tolerability, and pharmacokinetics of drug. All participants received SNB 101 in different cohorts, from 5 to 50 mg/m2 as SN-38. SNB 101 was administered intravenously to participants on day 1 and day 15 of each 28 day treatment cycle until progressive disease, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first. More information about SNB101P01 may be found on clinicaltrials.gov under trial identifier NCT04640480.
Currently Active (recruiting)
SNA-001(PANCRAXEL®) – Pancreatic Cancer
SNA-001 is anti-cancer drug for pancreatic, breast and non-small cell lung cancer. It adopted albumin nanoparticle drug delivery system to improve safety and efficacy of Taxol® (paclitaxel) that has been used for various solid tumors, especially for breast cancer. We will recruit patients for phase 1 study in South Korea, and will assess pharmacokinetic profile, safety and efficacy of SNA-001.